NASDAQ

Daxor Corporation - Closed End Fund (DXR)

310 Thanks from members

Daxor Corporation (DXR) exhibits neutral-to-cautious market sentiment as it navigates a transition out of closed-end fund status alongside a registered direct stock offering, featuring steady clinical product interest for its FDA-cleared blood volume analyzer and low trading liquidity.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →